Nan Hua Financial (00619.HK) plans to establish a joint venture company to enter high-growth sectors such as AI pharmaceuticals, beauty technology, and anti-aging consumer markets.

Zhtng Cijng APP News, Nanhua Financial (00619.HK) announced that on November 14, 2025, the company signed a Memorandum of Understanding with a company registered in China. The other party is mainly engaged in: (i) enabling technology - using artificial intelligence (AI) to develop tools, algorithms for accelerating data analysis, prediction and research; (ii) scientific basis - using AI to research molecular mechanisms to achieve transformation applications and meet clinical needs; and (iii) end products and clinical applications - from molecular research to drug pipeline research and real-world clinical applications. The joint venture company to be established will be located in Mainland China or Hong Kong, with the aim of: (a) developing an AI drug R&D platform and providing related technical services; (b) developing AI drug efficacy prediction platform services for global beauty customers; (c) developing disease and aging pipelines; and (d) developing anti-aging products for direct consumer sales.